Chondrosarcoma is a malignant tumor occupying the 2nd position in terms of frequency, all ages combined, after osteosarcoma [1]. Epidemiological data extracted from cancer registries in Europe indicate an annual incidence of ~0.1/100,000 inhabitants [2]. Mesenchymal chondrosarcoma of bone is a rare high-grade variant of chondrosarcoma (2-13%), which usually has an extra-skeletal (30-40%) or central intramedullary location (15-30%).